Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 10/20 | 0.67 |
| ▸ | LCK | P06239 | 5/20 | 0.64 |
| ▸ | KIT | P10721 | 2/20 | 0.64 |
| ▸ | SRC | P12931 | 1/20 | 0.64 |
| ▸ | CSF1R | P07333 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | APEX1 | P27695 | 1/20 | 0.56 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.56 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.56 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | RAF1 | P04049 | 1/20 | 0.55 |
| ▸ | KDR | P35968 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13878812 | 0.86 | LCK (0.61) | MAPK14LCKKITSRCCSF1R | |
| SCHEMBL13878809 | 0.85 | CSF1R (0.61) | MAPK14LCKKITSRCCSF1R | |
| SCHEMBL13878810 | 0.85 | CSF1R (0.71) | MAPK14LCKKITSRCCSF1R | |
| SCHEMBL13878808 | 0.85 | MAPT (0.75) | MAPK14LCKKITSRCCSF1R | |
| SCHEMBL22024681 | 0.83 | KIT (0.68) | MAPK14LCKKITSRCCSF1R | |
| SCHEMBL13878724 | 0.82 | BRAF (0.64) | MAPK14LCKKITSRCCSF1R | |
| SCHEMBL14288413 | 0.81 | MAPK14 (1.00) | MAPK14LCKMAPK13MAPK12MAPK11 | |
| SCHEMBL14288415 | 0.80 | MAPK14 (0.82) | MAPK14LCKMAPTPOLBMAPK13 | |
| SCHEMBL13878817 | 0.80 | LCK (0.59) | MAPK14LCKKITSRCCSF1R | |
| SCHEMBL13878811 | 0.80 | LCK (0.68) | MAPK14LCKKITSRCCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105250-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-04-23 | — | — | US | disclosed |
| US-20090105250-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105250-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ABL1, BCR, PDGFRB | MAPK14 461/4885LCK 56/4885KIT 683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.